Spero Therapeutics, Inc.
SPROAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 14, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 30, 2025 |
| Evercore ISI Group | downgrade | Outperform →In Line | Dec 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 2, 2024 |
| TD Cowen | downgrade | Buy →Hold | Nov 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 4, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 3, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 6, 2024 |
| TD Cowen | upgrade | Hold →Buy | Aug 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 14, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 5, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 14, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 1, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jul 20, 2023 |
| HC Wainwright & Co. | maintain | Buy | Apr 10, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 26, 2022 |
| Evercore ISI Group | upgrade | In Line →Outperform | Sep 23, 2022 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2022 |
| HC Wainwright & Co. | maintain | Buy | May 23, 2022 |
| Berenberg | downgrade | Buy →Hold | May 20, 2022 |
| Cantor Fitzgerald | maintain | Overweight | May 17, 2022 |
| Cowen & Co. | downgrade | Outperform →Market Perform | May 4, 2022 |
| Evercore ISI Group | downgrade | Outperform →In Line | May 4, 2022 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.47| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.16 | $-0.17 | — | — |
| May 13, 2026 | $-0.13 | $-0.18 | $258.0K | $258.0K |
| Mar 26, 2026 | $0.53 | $-0.20 | $41.3M | $26.0M |
| Nov 13, 2025 | $-0.13 | $-0.25 | $3.0M | $12.0M |
| Aug 12, 2025 | $-0.03 | $-0.38 | $11.8M | $11.0M |
| May 13, 2025 | $-0.25 | $-0.55 | $5.9M | $11.0M |
| Mar 27, 2025 | $-0.38 | $-0.35 | $9.4M | $6.2M |
| Nov 14, 2024 | $-0.32 | $-0.27 | $13.5M | $4.1M |
News
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today announced that the Compensation Committee of Spero's Board of Directors approved a grant, made on November 2, 2026, of an aggregate of 217,000 restricted stock unit awards (RSUs) and 434,000 stock options to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity I…
CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today announced that Esther Rajavelu, President and Chief Executive Officer, will participate in a “fireside chat” at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA. The company's leadership team will be available for one-on-one meetings with investors. The team…
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Amy Rock, Ph.D., appointed Chief Regulatory and Quality Officer, bringing extensive experience in global regulatory strategy, clinical development, and with approvals of novel immunotherapies Dae Gon Ha, Ph.D.
Spero Therapeutics NASDAQ: SPRO plans to initiate a Phase II trial of its lead immunology candidate, SP001, in immunoglobulin G4-related disease, or IgG4-RD, in the second quarter of 2027, Chief Executive Officer Esther Rajavelu said during a company presentation.
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, Spero's President and Chief Executive Officer, will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference to be held in New York City, on October 20th, 2026. Spero's leadership team will also be available for one-on-one m…
Global biosecurity alarms are flashing after an incident at an anti-plague research facility in Siberia sparked a severe public health response. Following the fatal lab exposure of a researcher in Irkutsk region to Yersinia pestis – the bacterium causing pneumonic plague – Russian officials placed several regional hospitals under quarantine and isolated nearly 200 contacts.
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero's Board of Directors approved grants, made on October 1, 2026, of an aggregate of 233,000 restricted stock unit awards (RSUs) and 323,000 stock options to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity I…
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero's Board of Directors approved a grant, made on September 1, 2026, of an aggregate of 102,000 restricted stock unit awards (RSUs) and 67,600 stock options to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equit…
CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, President and Chief Executive Officer, will present at the H.C.
Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript
Spero Therapeutics NASDAQ: SPRO used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for SP001, an antibody candidate the company plans to develop initially for IgG4-related disease.
CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.